Rheumatoid Arthritis

For more information on any of the studies listed below, call (405) 271-7805 or email clinic@omrf.org.

Anti-Inflammatory Effects of Honokiol on Activation of PBMC from Healthy Volunteers and RA Patients (ACTIVE)

ARA08: Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA) (ACTIVE – Open to Enrollment/Accrual)

Novel Mechanisms of IL-8 Regulation in Oklahoma Tribal Members Afflicted with Rheumatoid Arthritis (ACTIVE)

A 24-week, Phase 3, Multicentre, Randomised, Double blind, Efficacy and Safety Study Comparing GSK3196165 with Placebo and with Sarilumab, in Combination with Conventional Synthetic DMARDs in Participants with Moderately to Severely Active Rheumatoid Arthritis Who have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors, Protocol 202018 (ACTIVE – Open to Enrollment/Accrual)

A 52-week, Phase 3, Multicentre, Randomised, Double blind, Efficacy and Safety Study Comparing GSK3196165 with Placebo and with Tofacitinib, in Combination with Methotrexate in Participants with Moderately to Severely Active Rheumatoid Arthritis who have an Inadequate Response to Methotrexate, Protocol 201790 (ACTIVE – Open to Enrollment/Accrual)

Phase 3B/4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to a Tumor Necrosis Factor (TNF) Inhibitor in Subject with Rheumatoid Arthritis, Protocol A3921133 (ACTIVE – Closed to Enrollment/Accrual)

A Multi-Centre Long-Term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis Protocol 209564 (ACTIVE – Open to Enrollment/Accrual)

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis (RA-BRIDGE), Protocol I4V-MC-JAJA (ACTIVE – Closed to Enrollment/Accrual)